EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative evaluation of screening approaches for antiviral monoclonal antibody combinations

Maria K McClave iD, Samantha K Marzi iD, Ekaterina E Heldwein iD

Journal of Virology · 2026

DOI: 10.1128/jvi.00879-26 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Virology, 2026. Verfasst von Maria K McClave und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Viral, Antiviral Agents, Antibodies, Neutralizing. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibody (mAb) cocktails are increasingly used as antiviral therapeutics, but methods for evaluating mAb combination effects remain poorly standardized. To characterize interactions of recently isolated neutralizing mAbs targeting human cytomegalovirus glycoprotein B, we compared three screening approaches: checkerboard neutralization assays; DiaMOND, a high-throughput small-molecule interaction screening tool modified for mAb combinations; and EMERALD, a modified variable-ratio framework. As the most systematic approach, the checkerboard assay served as the baseline for subsequent comparisons. Most mAb combinations in checkerboard assays were classified as additive or antagonistic according to Loewe additivity-based analyses, regardless of whether the mAbs were competing or non-competing. Apparent synergy was observed primarily at saturating antibody concentrations. When adapted for mAb combinations, the DiaMOND framework produced interaction profiles that differed from checkerboard results under both concentration-based and dose-matched conditions. In contrast, EMERALD captured concentration-dependent interactions across variable mAb ratios and revealed asymmetric behavior, depending on which mAb was held constant. Together, these findings demonstrate that classifications of mAb interactions depend strongly on assay design, concentration range, and analytical framework. They further suggest that robust mAb synergy may be less common than often reported and highlight the need to evaluate antiviral mAb combinations across multiple experimental formats. IMPORTANCE Monoclonal antibody cocktails are gaining foothold as an important strategy for the prevention and treatment of viral infections. Synergistic antibody combinations are often reported, but whether they represent true synergy is unclear because classifications of interactions depend on the experimental design and analytical methods. Moreover, there is no broadly accepted methodology for evaluating interactions among antibody combinations. As a result, it remains unclear whether common approaches for screening antibody combinations accurately capture biologically relevant interactions. Here, we compared four approaches for evaluating antibody combinations to help define best experimental and analytical practices for studying antiviral antibody interactions. Our findings demonstrate that antibody interactions are highly dependent on assay design, choice of antibody concentrations, and timing of antibody exposure, suggesting that synergy and antagonism are not fixed properties of antibody pairs. These findings may be broadly applicable to studies of antiviral antibody combinations across diverse viral systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, ViralAntiviral AgentsAntibodies, NeutralizingHumansCytomegalovirusNeutralization TestsCombined Antibody TherapeuticsHigh-Throughput Screening AssaysAnimals

Stichwörter der Autor:innen

DiaMONDEMERALDantibody cocktailantibody combinationcheckerboard assayhuman cytomegalovirus (HCMV)monoclonal antibody (mAb)neutralizing antibody

Substanzen

Antibodies, MonoclonalAntibodies, ViralAntiviral AgentsAntibodies, NeutralizingCombined Antibody Therapeutics

Autor:innen und Institutionen

  • Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.
  • Graduate Program in Molecular Microbiology, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA.
  • Graduate Program in Genetics, Molecular, and Cellular Biology, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA.

ORCID-Profile: Maria K McClave, Samantha K Marzi, Ekaterina E Heldwein

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

McClave, M. K., Marzi, S. K., & Heldwein, E. E. (2026). Comparative evaluation of screening approaches for antiviral monoclonal antibody combinations. Journal of Virology. https://doi.org/10.1128/jvi.00879-26

Vancouver

McClave MK, Marzi SK, Heldwein EE. Comparative evaluation of screening approaches for antiviral monoclonal antibody combinations. Journal of Virology. 2026. doi:10.1128/jvi.00879-26

BibTeX
@article{McClave2026,
  author = {McClave, Maria K and Marzi, Samantha K and Heldwein, Ekaterina E},
  title = {Comparative evaluation of screening approaches for antiviral monoclonal antibody combinations},
  journal = {Journal of Virology},
  year = {2026},
  doi = {10.1128/jvi.00879-26}
}
Kostenlos starten →